Ensign Peak Advisors Inc Boosts Stake in Dyne Therapeutics, Inc. $DYN

Ensign Peak Advisors Inc grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1,220.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,073 shares of the company’s stock after buying an additional 245,923 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Dyne Therapeutics were worth $2,533,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Creative Planning increased its position in shares of Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in Dyne Therapeutics by 23.1% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock valued at $526,000 after purchasing an additional 10,350 shares during the period. Candriam S.C.A. increased its position in shares of Dyne Therapeutics by 13.1% during the 2nd quarter. Candriam S.C.A. now owns 524,161 shares of the company’s stock valued at $4,990,000 after purchasing an additional 60,793 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Dyne Therapeutics by 18.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 20,334 shares of the company’s stock worth $194,000 after purchasing an additional 3,155 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Dyne Therapeutics by 15.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,253,670 shares of the company’s stock worth $21,458,000 after purchasing an additional 298,165 shares during the period. 96.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. This represents a 1.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $21.17 on Thursday. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $31.32. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $3.02 billion, a PE ratio of -5.48 and a beta of 1.16. The firm’s 50 day simple moving average is $17.41 and its 200 day simple moving average is $13.58.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.05. As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the subject of several research reports. Royal Bank Of Canada increased their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Lifesci Capital raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Oppenheimer dropped their price objective on Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating on the stock in a research note on Wednesday, November 12th. Finally, Evercore ISI reissued an “outperform” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Thursday, November 6th. Four research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.47.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.